/C O R R E C T I O N -- Jazz Pharmaceuticals, Inc./

In the news release, FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD), issued earlier

PRNewswire -- Feb. 28
FCMN Contact: kelly.mckenna@mslpr.com

Source: Jazz Pharmaceuticals, Inc.

Web site: http://www.jazzpharmaceuticals.com/

2008-02-28 22:08:53 0301386 PRNEWSWIRE